ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

opevesostat

Also written as “Opevesostat”, “MK-5684” and “ODM-208”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasms · Kidney Failure, Chronic, led by 2 companies.

Drug pageOpevesostat: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 13, 202313 company-led studies, 5 open or runningLicense: Orion → Merck, Jul 2024Next primary completion: Nov 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only124 open or runningphase 3since Nov 13, 2023Oct 23, 2023Nov 4, 2027phase 2 · NCT06979596
Orion Corporation, Orion Pharma11 open or runningphase 2since Feb 12, 2018Feb 12, 2018none ahead
  • Named in Merck’s own pipeline as opevesostat (MK-5684), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseMerck licensed it from Orion, for worldwide rights, in place of their co-development.Announced Jul 1, 2024 · Source: Merck, Jul 1, 2024

History and studies of Orion Corporation, Orion Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2018First study: phase 2 study in Prostate Cancer MetastaticFirst studyNCT03436485 · 204 enrolled · United States, Finland, France and more
  2. Aug 6, 2023Named opevesostatINNProposed as its International Nonproprietary Name in WHO's List 129 · before, MK-5684, ODM-208
  3. Jul 1, 2024Merck licensed it from OrionLicenseWorldwide rights, in place of their co-development · announced · Merck

TargetBeta

“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all ste…”NCIt, read by Claude
“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), ”NCIt, by rule

Other programs on CYP11A1

ProgramCompanyFurthest phaseStudies
CYP11A1 Inhibitor ACE-232ruleacerand-therapeutics-hong-kong-limitedphase 11

Studies

The one study Orion Corporation, Orion Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03436485Prostate Cancer Metastatic · United States, Finland, France and more2Active, not recruitingOct 31, 2026204

How it is read

Names in the registry

  • “Opevesostat”, 9 entries
  • “MK-5684”, 2 entries
  • “ODM-208”, 1 entry
  • “[¹⁴C]Opevesostat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.